NASDAQ · ECOR
electroCore, Inc.
$8.11-$0.31 (-3.68%)
electroCore, Inc.’s quoted price sits in the lower half of its reported 52-week range, 36.14% below the high.
Loading market information…
NASDAQ · NMTC · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
NeuroOne Medical Technologies Corporation’s quoted price sits in the lower half of its reported 52-week range, 84.15% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
NeuroOne Medical Technologies Corporation’s next earnings report is currently expected on Dec 15, 2026, with estimated earnings per share of -$0.19. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow NeuroOne Medical Technologies Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
NeuroOne Medical Technologies Corporation functions as a specialized medical technology enterprise. Its core mission involves the invention and market deployment of sophisticated thin-film electrode systems. These systems are crafted for diverse neurophysiological applications, such as the continuous recording of electroencephalograms (cEEG) and stereoelectroencephalograms (sEEG), as well as therapeutic interventions including spinal cord stimulation, brain stimulation, and ablation procedures. The technology aims to assist individuals afflicted by conditions like epilepsy, Parkinson's disease, dystonia, essential tremors, persistent pain arising from unsuccessful back surgeries, and a variety of other neurological disorders. Furthermore, the company has forged a crucial partnership with RBC Medical Innovations to engineer a radio frequency ablation generator. This generator is designed to integrate seamlessly with NeuroOne's unique dual-function electrode, allowing for both the precise monitoring of brain electrical activity and the targeted ablation of brain tissue using a singular instrument. The corporate headquarters are situated in Eden Prairie, Minnesota.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:15 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $1.70M-6.64% vs estimate |
| Q2 2025 | May 13, 2025 | -$0.42+22.22% vs estimate | $1.39M+9.43% vs estimate |
|---|
| Q1 2025 | Feb 12, 2025 | $0.36+160.0% vs estimate | $6.30M+200.0% vs estimate |
|---|
| Q4 2024 | Dec 17, 2024 | -$0.66-22.22% vs estimate | $272.28K-84.87% vs estimate |
|---|
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $5.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$8.11-$0.31 (-3.68%)
electroCore, Inc.’s quoted price sits in the lower half of its reported 52-week range, 36.14% below the high.
$3.51+$0.51 (+16.83%)
Hyperion DeFi, Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.95% below the high.
$1.30+$0.04 (+3.17%)
Myomo, Inc.’s quoted price sits in the upper half of its reported 52-week range, 31.22% below the high.
$2.23+$0.06 (+2.93%)
Alterity Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 62.08% below the high.
$9.81-$0.07 (-0.71%)
Star Equity Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 17.63% below the high.
$2.98+$0.01 (+0.34%)
111, Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.32% below the high.
$4.40-$0.84 (-16.03%)
Cytosorbents Corporation’s quoted price sits in the lower half of its reported 52-week range, 74.12% below the high.
$0.19-$0.06 (-24.8%)
Baird Medical Investment Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 94.92% below the high.
